Stephanie O Klopfer, Jon E Stek, Maria Petrecz, Keith S Reisinger, Steven B Black, Michelle G Goveia, Ouzama Nicholson, Julie L Gardner, Anthony D Grosso, Michelle L Brown, Barbara J Kuter, Florian P Schödel
BACKGROUND: In randomized clinical studies, over 11,800 children, 12 months to 6 years of age, were administered ProQuad(®), a combination measles, mumps, rubella, and varicella vaccine (MMRV). This paper describes the safety following a 2-dose regimen of MMRV administered to children in the second year of life. METHODS: Safety data from five clinical studies were combined for all children who were scheduled to receive two doses of MMRV ∼3-6 months apart. All vaccinated children were followed for safety following each dose of MMRV...
December 12, 2014: Vaccine